DR. WILLIAM L. GOLDEN M.D.
Prescription History 1598705147
Obstetrics & Gynecology - Gynecology in Auburn, AL

NPI Status: Active since June 08, 2006

Contact Information

2375 CHAMPIONS BLVD
AUBURN, AL
ZIP 36830
Phone: (334) 745-6447
Fax: (334) 742-0713

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. WILLIAM L. GOLDEN M.D., an active Gynecology specialist practicing in Auburn, AL. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 326 documented patient claims. Among these therapy options, the most frequently utilized medication is Estradiol, which accounts for 186 claims alone.


Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 186
30-Day Fills 455.1
Days Supply 13,653
AL State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills110.3
Peer Average Days Supply3,291
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 264.7% higher than the standard regional baseline profile for AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,029.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$37.79

State Avg Cost Per Claim

$47.02

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estradiol (Twice Weekly)

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 11
30-Day Fills 29.0
Days Supply 868
AL State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills45.1
Peer Average Days Supply1,327
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.0% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,992.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$181.15

State Avg Cost Per Claim

$128.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estradiol-Norethindrone Acetat

Generic Formulation: Estradiol/Norethindrone AcetSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 52
30-Day Fills 111.4
Days Supply 3,304
AL State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills34.8
Peer Average Days Supply1,022
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 173.7% higher than the standard regional baseline profile for AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,247.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$139.37

State Avg Cost Per Claim

$137.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 female hormones: an estrogen (such as conjugated estrogen, estradiol) and a progestin (such as medroxyprogesterone, norethindrone, norgestimate). Some brands of this medication may contain progesterone instead of a progestin. Progesterone and progestin both act like the form of the natural hormone (progesterone) produced by your body. This medication is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. The progestin or progesterone in this medication helps to reduce the risk of cancer of the uterus which can be caused by using estrogen. Women who have had their uterus removed do not need the progestin or progesterone. They should not use this combination medication. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen/progestin treatment.

Medroxyprogesterone Acetate

Generic Formulation: Medroxyprogesterone AcetateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 32
30-Day Fills 68.0
Days Supply 2,020
AL State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills51.1
Peer Average Days Supply1,437
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 28.0% more claims than the standard regional baseline profile for AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $515.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.10

State Avg Cost Per Claim

$19.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms.

Therapeutic Applications

This medication is used to prevent pregnancy. Medroxyprogesterone is like a natural hormone made by the body. Using this medication does not protect you or your partner against sexually transmitted diseases (such as HIV, gonorrhea, chlamydia).

Myrbetriq

Generic Formulation: MirabegronSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 21
30-Day Fills 23.3
Days Supply 700
AL State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills67.4
Peer Average Days Supply1,881
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.3% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,110.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$529.07

State Avg Cost Per Claim

$602.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Premarin

Generic Formulation: Estrogens, ConjugatedSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 24
30-Day Fills 56.0
Days Supply 1,680
AL State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills38.9
Peer Average Days Supply1,148
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,457.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$477.39

State Avg Cost Per Claim

$352.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Therapeutic Applications

This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. WILLIAM L. GOLDEN M.D. provides transparency into local medical care patterns within Auburn, AL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.